Compositions and methods for treating cancer
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsDavid DiLillo, Thomas Craig Meagher
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions and methods for targeted treatment of cancer. The present disclosure provides chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric antigen receptors are specific for a low density cancer antigen or peptide in groove antigen.
Claims27
A CAR polypeptide comprising:
- a) at least one intracytoplasmic/costimulatory region comprising a cluster of differentiation 28 zeta (CD28/ζ) domain,
- b) at least one intracytoplasmic signaling region comprising a cluster of differentiation 3 zeta (CD3/ζ) domain, and
- c) an antigen binding domain specific for a peptide in groove cancer antigen.
3-4. (canceled)
7-8. (canceled)
A CAR polypeptide having antigenic specificity for a peptide in groove cancer antigen and the CAR comprises an amino acid sequence set forth in SEQ ID NOs:
- 7, 9, 11, 13, 30, or 34.
(canceled)
(canceled)
18-19. (canceled)
23-25. (canceled)
A method of treating a tumor in a subject, the method comprising administering a composition comprising cells expressing a CAR polypeptide comprising:
- a) at least one intracytoplasmic/costimulatory region comprising a cluster of differentiation 28 zeta (CD28/ζ) domain,
- b) at least one intracytoplasmic signaling region comprising a cluster of differentiation 3 zeta (CD3/ζ) domain, and
- c) an antigen binding domain specific for a peptide in groove antigen.
(canceled)
Dependencies are inferred from the claim text.